Kumaraguru Raja
Stock Analyst at Brookline Capital
(0.08)
# 4,425
Out of 5,046 analysts
16
Total ratings
14.29%
Success rate
-33.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INTS Intensity Therapeutics | Upgrades: Buy | $3 | $0.73 | +310.85% | 1 | Aug 12, 2025 | |
| PALI Palisade Bio | Maintains: Buy | $16 | $2.07 | +672.95% | 2 | May 13, 2025 | |
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $1.65 | +445.45% | 1 | Dec 18, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $3.25 | +146.15% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $12.94 | +672.80% | 2 | May 30, 2024 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $1.26 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $150 | $0.35 | +42,806.18% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $2.57 | +483.66% | 1 | Jun 29, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $5.26 | +299.24% | 1 | Jan 31, 2023 | |
| MNPR Monopar Therapeutics | Reinstates: Buy | $90 | $86.16 | +4.46% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $290 → $310 | $2.95 | +10,408.47% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33,600 | $3.42 | +982,356.14% | 1 | Sep 21, 2021 |
Intensity Therapeutics
Aug 12, 2025
Upgrades: Buy
Price Target: $3
Current: $0.73
Upside: +310.85%
Palisade Bio
May 13, 2025
Maintains: Buy
Price Target: $16
Current: $2.07
Upside: +672.95%
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $1.65
Upside: +445.45%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $3.25
Upside: +146.15%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $12.94
Upside: +672.80%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.26
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $150
Current: $0.35
Upside: +42,806.18%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $2.57
Upside: +483.66%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $5.26
Upside: +299.24%
Monopar Therapeutics
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $86.16
Upside: +4.46%
May 18, 2022
Maintains: Buy
Price Target: $290 → $310
Current: $2.95
Upside: +10,408.47%
Sep 21, 2021
Initiates: Buy
Price Target: $33,600
Current: $3.42
Upside: +982,356.14%